98. Eosinophilic gastrointestinal disease
[
78 clinical trials,
85 drugs（DrugBank:
33 drugs),
31 target genes / 123 target pathways ]
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro intestinal disorder", "EGID", "Neonatal food protein induced enterocolitis", "N FPIES"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03678545 | May 2020 | 30 September 2019 | Dupilumab in Eosinophilic Gastritis | A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis | Eosinophilic Gastritis;Eosinophilic Gastroenteritis | Drug: Dupilumab (blinded);Drug: Placebo (blinded);Drug: Dupilumab (open-label) | Children's Hospital Medical Center, Cincinnati | Regeneron Pharmaceuticals | Not recruiting | 18 Years | 70 Years | All | 40 | Phase 2 | United States |
| 2 | NCT02873468 | February 2020 | 14 October 2019 | Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis | Randomized, Double-blind, Multicentric, Parallel, National, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Florence 30 µg/mL;Drug: Florence 60 µg/mL;Drug: Florence 90 µg/mL;Other: Placebo | EMS | Not recruiting | 18 Years | N/A | All | 116 | Phase 2 | ||
| 3 | NCT04149470 | December 2019 | 11 November 2019 | Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) | Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) | Eosinophilic Esophagitis | Drug: Omeprazole 20mg BID | University of Colorado, Denver | Children's Hospital Colorado | Not recruiting | 8 Years | 22 Years | All | 90 | Phase 4 | |
| 4 | NCT03615950 | October 1, 2019 | 22 July 2019 | Effects of Swallowed Steroids on Bone Density and Growth in Pediatric Eosinophilic Esophagitis | Effects of Swallowed Corticosteroids on Bone Mineral Density and Growth Velocity in Children With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Diagnostic Test: Bone Mineral Density (DEXA) scan;Diagnostic Test: Vitamin D Measurement;Diagnostic Test: Height measurement;Other: Assessment of medication compliance | Arkansas Children's Hospital Research Institute | University of Arkansas | Recruiting | 5 Years | 12 Years | All | 60 | Phase 3 | United States |
| 5 | NCT03656380 | March 20, 2019 | 14 October 2019 | Mepo for EoE Study | A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms | EoE;Eosinophilic Esophagitis | Drug: Mepolizumab 300 mg;Drug: Mepolizumab 100 mg;Other: Placebo | University of North Carolina, Chapel Hill | GlaxoSmithKline;University of Utah;Northwestern University;Minnesota Gastroenterology, P.A. | Recruiting | 16 Years | 75 Years | All | 72 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03664960 | November 14, 2018 | 4 March 2019 | An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis | A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis | Eosinophilic Gastritis;Eosinophilic Gastroenteritis | Drug: AK002 | Allakos, Inc. | Recruiting | 18 Years | 80 Years | All | 60 | Phase 2 | United States | |
| 7 | NCT03633617 | September 24, 2018 | 4 November 2019 | Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis | Drug: Dupilumab;Drug: Placebo | Regeneron Pharmaceuticals | Sanofi | Recruiting | 12 Years | N/A | All | 425 | Phase 3 | United States;Australia;Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom |
| 8 | NCT03496571 | July 18, 2018 | 26 August 2019 | A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis | Eosinophilic Gastritis;Eosinophilic Gastroenteritis | Drug: AK002;Other: Placebo | Allakos, Inc. | Not recruiting | 18 Years | 80 Years | All | 65 | Phase 2 | United States | |
| 9 | NCT03245840 | October 5, 2017 | 4 November 2019 | Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) | A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis (EoE) | Drug: Budesonide oral suspension | Shire | Recruiting | 11 Years | 55 Years | All | 100 | Phase 3 | United States | |
| 10 | NCT03191864 | June 30, 2017 | 18 December 2018 | Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) | FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: APT-1011;Drug: Placebo | Adare Pharmaceuticals, Inc. | Not recruiting | 18 Years | 75 Years | All | 100 | Phase 2 | United States;Belgium;Canada;Germany;Spain;Switzerland | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03290482 | June 19, 2017 | 26 August 2019 | Natural History of Eosinophilic Esophagitis | Natural History of Eosinophilic Esophagitis: A Longitudinal Follow-up Over 10 Years | Eosinophilic Esophagitis | Diagnostic Test: Barium Esophagram;Device: EsophaCap;Diagnostic Test: Physical Examination and Questionnaires | Mayo Clinic | Recruiting | 18 Years | N/A | All | 65 | N/A | United States | |
| 12 | NCT03029091 | January 19, 2017 | 20 May 2019 | An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) | A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder | Eosinophilic Esophagitis | Drug: Losartan Potassium | Children's Hospital Medical Center, Cincinnati | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS) | Not recruiting | 5 Years | 25 Years | All | 15 | Phase 2 | United States |
| 13 | EUCTR2017-003737-29-NL | 30 April 2019 | Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receives medication without active substance), phase II/III study on the efficacy and tolerability of oral budesonide suspension in comparison with placebo in children and adolescents with eosinophilic esophagitis | Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophilic esophagitis - Budesonide oral suspension vs. placebo in pediatric eosinophilic esophagitis | Active eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis MedDRA version: 20.1 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Budesonide oral suspension [0.2 mg/ml] Pharmaceutical Form: Oral suspension INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Oral suspension Route of administration of the placebo: Oral use | Dr. Falk Pharma GmbH | Not Available | Female: yes Male: yes | 75 | Phase 2;Phase 3 | Portugal;Greece;Spain;Israel;Germany;Netherlands;United Kingdom | ||||
| 14 | NCT04069429 | July 2016 | 22 October 2019 | Radiation Dose in Humans From Orally Administered Tc99m-Heparin | Radiation Dose in Humans From Orally Administered Tc99m-Heparin | Eosinophilic Esophagitis | Radiation: Computerized Tomography scan;Radiation: Single Photon Emission Computed Tomography scans;Drug: Technetium Tc 99M;Radiation: Planar Images;Procedure: Esophagogastroduodenoscopy | University of Utah | Recruiting | 18 Years | 70 Years | All | 17 | Early Phase 1 | United States | |
| 15 | NCT02778867 | May 20, 2016 | 30 September 2019 | SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study | Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial | Eosinophilic Gastrointestinal Disorders (EGIDs);Eosinophilic Esophagitis (EoE) | Drug: Flovent;Other: elimination diet therapy | Children's Hospital Medical Center, Cincinnati | Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | 18 Years | 60 Years | All | 130 | Phase 2/Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02736409 | April 29, 2016 | 6 May 2019 | An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) | A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis (EoE) | Drug: Oral Budesonide Suspension (OBS);Drug: Placebo | Shire | Not recruiting | 11 Years | 55 Years | All | 200 | Phase 3 | United States;United Kingdom | |
| 17 | JPRN-UMIN000021041 | 2016/02/15 | 10 September 2019 | A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis | A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis - A study investigating the therapeutic effect of vonoprazan on the patients with proton pump inhibitor resistant eosinophilic esophagitis | Eosinophilic esophagitis | administration of Vonoprazan (20mg/day for 2 months) | Second department of Internal Medicine, Shimane University Faculty of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 5 | Not selected | Japan | |
| 18 | NCT02493335 | January 15, 2016 | 25 February 2019 | Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis | Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Budesonide 0.5mg orodispersible tablet twice daily;Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice daily | Dr. Falk Pharma GmbH | Not recruiting | 18 Years | 75 Years | All | 204 | Phase 3 | Germany | |
| 19 | NCT02610816 | January 2016 | 20 June 2016 | Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids | Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids | Eosinophilic Esophagitis;Eosinophilic Gastrointestinal Disorders (EGIDs), | Other: elimination diet therapy;Drug: Flovent (fluticasone propionate) | Children's Hospital Medical Center, Cincinnati | Collaborator: Patient Centered Outcome Research Institute (PCORI) | Recruiting | 6 Years | 17 Years | Both | 292 | Phase 2/Phase 3 | United States |
| 20 | EUCTR2014-001485-99-DE | 08/12/2015 | 30 April 2019 | Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets in comparison with placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis | Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis - Maintenance of remission with budesonide effervescent tabl. vs. placebo in eosinophilic esophagitis | Maintenance of remission in eosinophilic esophagitis MedDRA version: 20.1 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: 1 mg budesonide effervescent tablet for orodispersible use Product Code: BUET 1mg Pharmaceutical Form: Effervescent tablet INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Effervescent tablet Route of administration of the placebo: Oral use Product Name: 0.5 mg budesonide effervescent tablet for orodispersible use Product Code: BUET 0.5 mg Pharmaceutical Form: Effervescent tablet INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Effervescent tablet Route of administration of the placebo: Oral use | Dr. Falk Pharma GmbH | Authorised | Female: yes Male: yes | 204 | Phase 3 | Belgium;Spain;Denmark;Netherlands;Germany;United Kingdom;Switzerland | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02605837 | December 7, 2015 | 26 August 2019 | A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved | Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study | Eosinophilic Esophagitis (EoE) | Drug: Oral Budesonide Suspension (OBS);Drug: Placebo | Shire | Not recruiting | 11 Years | 55 Years | All | 420 | Phase 3 | United States | |
| 22 | NCT02579876 | October 2015 | 15 July 2019 | Milk Patch for Eosinophilic Esophagitis | A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children | Eosinophilic Esophagitis;Milk Allergy | Drug: Viaskin Milk 500 mcg;Drug: Viaskin Placebo | Children's Hospital of Philadelphia | DBV Technologies | Not recruiting | 4 Years | 17 Years | All | 20 | Phase 2 | United States |
| 23 | EUCTR2014-001484-12-DE | 22/09/2015 | 9 January 2017 | Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (tested against tablets without active substance), phase III study on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis | Double-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis - Induction of remission with budesonide effervescent tablets vs. placebo in eosinophilic esophagitis | Active eosinophilic esophagitis MedDRA version: 19.0 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: 1 mg budesonide effervescent tablet for orodispersible use Product Code: BUET 1mg Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Oral use | Dr. Falk Pharma GmbH | Not Recruiting | Female: yes Male: yes | 90 | Phase 3 | Spain;Belgium;Netherlands;Germany;Switzerland | |||
| 24 | NCT02379052 | June 3, 2015 | 26 February 2018 | Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) | A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Dupilumab;Drug: Placebo | Regeneron Pharmaceuticals | Sanofi | Not recruiting | 18 Years | 65 Years | All | 47 | Phase 2 | United States |
| 25 | NCT02434705 | April 2015 | 26 August 2019 | Food Antigen in Eosinophilic Esophagitis | Protocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Other: Antigen (wheat base soy sauce) spray | Mayo Clinic | Recruiting | 18 Years | 80 Years | All | 20 | N/A | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02019758 | January 1, 2015 | 3 September 2018 | Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis | Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Oral Viscous Budesonide;Drug: Fluticasone MDI;Drug: Placebo slurry;Drug: Placebo inhaler | University of North Carolina, Chapel Hill | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 16 Years | 80 Years | All | 173 | Phase 4 | United States |
| 27 | NCT02353078 | January 2015 | 16 December 2017 | The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis | The Effect of Sucralfate Slurry on Dilated Intercellular Spaces, Tight Junctions, Mucosal Impedance and Mucosal Activity in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Sucralfate;Procedure: Intraluminal Impedance;Device: Intraluminal Impedance | Mayo Clinic | Not recruiting | 18 Years | 80 Years | All | 3 | Early Phase 1 | United States | |
| 28 | NCT02371941 | December 2014 | 11 June 2018 | Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis | A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: oral cromolyn sodium;Drug: Placebo | University of Tennessee | Not recruiting | 2 Years | 18 Years | All | 16 | Phase 4 | United States | |
| 29 | NCT02314455 | September 2014 | 8 August 2016 | Esophageal Absorption in EoE | Esophageal Absorption in Eosinophilic Esophagitis | Eosinophilic Esophagitis | Other: D-xylose | Mayo Clinic | Not recruiting | 18 Years | 80 Years | Both | 14 | N/A | United States | |
| 30 | NCT02098473 | August 31, 2014 | 16 December 2017 | Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis | A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: RPC4046;Drug: Placebo | Celgene | Not recruiting | 18 Years | 65 Years | All | 100 | Phase 2 | United States;Canada;Switzerland | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02058537 | February 2014 | 19 October 2017 | Bethanechol for Eosinophilic Esophagitis | Bethanechol for Treatment of Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis (EoE) | Drug: Bethanechol | University of Iowa | Not recruiting | 18 Years | 75 Years | All | 2 | Phase 2 | United States | |
| 32 | NCT02125851 | January 2014 | 19 February 2015 | Comparison of Esophageal Clearance Times of Oral Budesonide Preparations | Comparison of Esophageal Clearance Times of Oral Budesonide Preparations | Eosinophilic Esophagitis | Other: Xanthan Gum;Other: Honey | Walter Reed National Military Medical Center | Not recruiting | 18 Years | 75 Years | Both | 24 | N/A | United States | |
| 33 | EUCTR2014-002465-30-IT | 2 October 2017 | Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis. | Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis. | Eosinophilic Esophagitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Budesonide Product Code: Budesonide Pharmaceutical Form: Oral suspension INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 0.19-0.21 | Dip. Pediatria UOC Gastroenterologia ed Epatologia Pediatrica | Not Available | Female: yes Male: yes | Phase 2 | Italy | |||||
| 34 | EUCTR2012-005842-39-SE | 20/12/2013 | 1 October 2018 | Treatment of patients with eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study | Treatment of eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study for evaluation of treatment effect on group level including symtom questionnaires | Eosinphilic Esophagitis;Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09] | Trade Name: Nasonex Pharmaceutical Form: Oromucosal spray Pharmaceutical form of the placebo: Suspension and solution for spray Route of administration of the placebo: Oromucosal use | NU-sjukvården, Norra Älvsborgs Länssjukhus | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Sweden | |||
| 35 | NCT01929824 | August 2013 | 14 October 2019 | Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE) | A Pilot Study: Nasal Nitric Oxide Levels in Eosinophilic Esophagitis. | Eosinophilic Esophagitis | Other: Oral Nitric Oxide testing | Mayo Clinic | Not recruiting | 18 Years | N/A | All | 50 | Phase 1/Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01821898 | July 9, 2013 | 20 August 2018 | Eosinophilic Esophagitis Clinical Therapy Comparison Trial | Eosinophilic Esophagitis Clinical Therapy Comparison Trial | Eosinophilic Esophagitis | Drug: Oral Budesonide;Other: Elimination diet | Baylor College of Medicine | Not recruiting | 3 Years | 17 Years | All | 60 | Phase 2 | United States | |
| 37 | NCT01808196 | April 2013 | 5 February 2018 | Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD | A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. | Eosinophilic Esophagitis;Connective Tissue Disorders | Drug: Losartan Potassium | Children's Hospital Medical Center, Cincinnati | Not recruiting | 5 Years | 21 Years | All | 6 | Phase 2 | United States | |
| 38 | NCT01814059 | March 7, 2013 | 16 July 2018 | Sirolimus for Eosinophil-Associated Gastrointestinal Disorders | A Phase 1, Open-Label Study of Sirolimus in Eosinophil-Associated Gastrointestinal Disorders | Eosinophilic Gastroenteritis;Eosinophilic Esophagitis | Drug: sirolimus | National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | 18 Years | 65 Years | All | 4 | Phase 1 | United States | |
| 39 | NCT01865825 | March 2013 | 16 December 2017 | Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? | PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis? | Erosive Esophagitis | Radiation: Esophageal Barium Xray | Mayo Clinic | Not recruiting | 18 Years | N/A | All | 20 | N/A | United States | |
| 40 | NCT01846962 | November 2012 | 11 June 2018 | Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis | COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) | Eosinophilic Esophagitis | Drug: Budesonide;Drug: Fluticasone;Behavioral: six-foods elimination diet;Drug: Oral Viscous Budesonide (OVB) | Azienda Policlinico Umberto I | Not recruiting | 6 Months | 18 Years | All | 64 | Phase 4 | Italy | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT01685034 | October 2012 | 29 August 2016 | Allergy Immunotherapy in the Management of Eosinophilic Esophagitis | Evaluation of the Clinical, Endoscopic and Histologic Effects of Environmental Allergy Immunotherapy in the Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Biological: Allergy immunotherapy (allergy shots) | United States Naval Medical Center, San Diego | Not recruiting | 18 Years | N/A | Both | 0 | N/A | ||
| 42 | NCT01642212 | July 2012 | 19 October 2017 | OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension | Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension | Eosinophilic Esophagitis | Drug: Oral Budesonide Suspension (MB-9);Drug: Placebo | Shire | Not recruiting | 11 Years | 40 Years | All | 93 | Phase 2 | United States | |
| 43 | NCT01479231 | March 2012 | 19 February 2015 | Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis | Predictors of PPI Response in Eosinophilic Esophagitis | Gastroesophageal Reflux Disease;Eosinophilic Esophagitis;Dysphagia | Drug: dexlansoprazole | Mayo Clinic | Not recruiting | 18 Years | 80 Years | Both | 0 | Phase 1/Phase 2 | United States | |
| 44 | EUCTR2009-016692-29-BE | 20/02/2012 | 21 August 2017 | A study to investigate the efficacy and tolerance of budesonide tablets and suspension in patients suffering from esophagitis over a 14 day period | Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspension vs. placebo in patients with eosinophilic esophagitis - Budesonide effervescent tablets vs. viscous budesonide suspension vs. placebo in EE | Active eosinophilic esophagitis MedDRA version: 14.1 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: 1mg budesonide effervescent tablet for orodispersible use Product Code: BUET 1mg Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Current Sponsor code: BUET 1 mg Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Oral use Product Name: 2mg budesonide effervescent tablet for orodispersible use Product Code: BUET 2mg Pharmaceutical Form: Orodispersible tablet INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Current Sponsor code: BUET 2 mg Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Orodispersible tablet Route of administration of the placebo: Oral use Product Name: Budesonide [0.4mg/ml] viscous suspension Product Code: BUU 0.4mg/ml Pharmaceutical Form: Oral suspension INN or Proposed INN: BUDESONIDE CAS Number: 51333-22-3 Current Sponsor code: BUU: Budesonide viscous suspension Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.4- Pharmaceutical form of the placebo: Oral suspension Route of administration of the placebo: Oral use | Dr. Falk Pharma GmbH | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Belgium;Germany;Switzerland | |||
| 45 | NCT01498497 | January 2012 | 16 December 2017 | A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021 | Six Month Safety Follow-up Study for PR-021 [Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Eosinophilic Esophagitis Subjects] | Eosinophilic Esophagitis | Drug: EUR-1100;Drug: Placebo | Forest Laboratories | Not recruiting | 12 Years | 55 Years | All | 14 | N/A | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT01702701 | January 2012 | 9 September 2019 | Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone | Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone | Eosinophilic Esophagitis;Dysphagia | Drug: Montelukast;Drug: Fluticasone | Medical College of Wisconsin | Not recruiting | 18 Years | N/A | All | 0 | Phase 3 | United States | |
| 47 | NCT01458418 | December 2011 | 2 March 2015 | A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children | A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children | Eosinophilic Esophagitis | Drug: Montelukast;Other: placebo;Drug: 5 mg Montelukast | Children's Mercy Hospital Kansas City | Not recruiting | 2 Years | 17 Years | Both | 4 | N/A | United States | |
| 48 | NCT01386112 | September 2011 | 19 February 2015 | Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis | A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis | Drug: EUR-1100;Drug: placebo | Aptalis Pharma | Not recruiting | 12 Years | 55 Years | Both | 24 | Phase 1/Phase 2 | United States | |
| 49 | NCT01624129 | January 2011 | 19 February 2015 | New Serological Markers for Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Fluticasone | Technische Universität München | Recruiting | 18 Years | 80 Years | Both | 20 | N/A | Germany | ||
| 50 | NCT01056783 | August 2010 | 19 February 2015 | Proof of Concept Study of OC000459 in Eosinophilic Esophagitis | A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: OC000459;Drug: Placebo | Oxagen Ltd | Not recruiting | 18 Years | 75 Years | Both | 26 | Phase 2 | Switzerland | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT01170234 | August 2010 | 23 April 2019 | Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis | Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis | Eosinophilic Esophagitis | Device: NIOX MINO® Airway Inflammation Monitor | Tufts Medical Center | Not recruiting | 7 Years | 65 Years | All | 14 | Phase 3 | United States | |
| 52 | NCT01016223 | March 2010 | 19 February 2015 | A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Beclomethasone dipropionate;Drug: placebo | Penn State University | Not recruiting | 18 Years | 65 Years | Both | 20 | Phase 1 | United States | ||
| 53 | NCT02038894 | December 2009 | 6 October 2015 | Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies | Comparison Of Different Anesthetic Techniques In Children Undergoing Esophagogastroduodenoscopies | Eosinophilic Esophagitis | Drug: Intubated with Sevoflurane (IS);Drug: Intubated with Propofol (IP);Drug: Zofran - no intubation;Drug: Propofol | Children's Hospital Medical Center, Cincinnati | Not recruiting | 1 Year | 12 Years | Both | 179 | N/A | United States | |
| 54 | NCT01022970 | November 2009 | 19 February 2015 | Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis | A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis | Drug: QAX576 placebo;Drug: QAX576 | Novartis Pharmaceuticals | Not recruiting | 18 Years | 50 Years | Both | 25 | Phase 2 | United States | |
| 55 | NCT00961233 | October 2009 | 19 October 2017 | Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE) | Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE): Esophageal Medication Distribution, Treatment Response, and Effect on the Adrenal Axis. | Eosinophilic Esophagitis | Drug: inhaled/swallowed budesonide;Drug: viscous/swallowed budesonide | University of North Carolina, Chapel Hill | AstraZeneca | Not recruiting | 18 Years | N/A | All | 25 | N/A | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT01040598 | June 2009 | 19 February 2015 | Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model | Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model | Eosinophilic Esophagitis | Biological: Omalizumab | O & O Alpan LLC | Genentech, Inc. | Not recruiting | 12 Years | 76 Years | Both | 19 | Phase 1 | United States |
| 57 | NCT00762073 | November 2008 | 19 October 2017 | Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis | Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents | Eosinophilic Esophagitis (EoE) | Drug: budesonide;Drug: placebo | Shire | Not recruiting | 2 Years | 18 Years | All | 82 | Phase 2 | United States | |
| 58 | NCT00880906 | August 2008 | 16 December 2017 | Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis | Prospective, Single-Blinded, Randomized Controlled Trial With Sham Comparing Standard Therapy With or Without Esophageal Dilatation in Patients With Eosinophilic Esophagitis | Suspected Eosinophilic Esophagitis | Procedure: Esophageal dilation;Drug: Steroid and Proton Pump Inhibitor Therapy | Vanderbilt University | Takeda | Not recruiting | 18 Years | 75 Years | All | 50 | N/A | United States |
| 59 | NCT00635089 | July 2008 | 16 December 2017 | Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis | An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 | Eosinophilic Esophagitis | Drug: reslizumab | Ception Therapeutics | Cephalon | Not recruiting | 5 Years | N/A | All | 190 | Phase 3 | United States;Canada |
| 60 | NCT00728481 | May 2008 | 19 October 2017 | The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis | The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis | Eosinophilic Esophagitis;Gastroesophageal Reflux Disease;EE;GERD | Drug: Esomeprazole;Drug: Budesonide | Mayo Clinic | AstraZeneca | Not recruiting | 18 Years | 80 Years | All | 51 | Phase 2/Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT00895817 | April 2008 | 19 October 2017 | Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis | Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Swallowed fluticasone;Drug: Esomeprazole | Walter Reed Army Medical Center | Not recruiting | 18 Years | N/A | All | 42 | N/A | United States | |
| 62 | NCT00538434 | March 2008 | 19 October 2017 | Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years | An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years | Eosinophilic Esophagitis | Biological: Reslizumab;Other: Saline | Ception Therapeutics | Not recruiting | 5 Years | 18 Years | All | 227 | Phase 2/Phase 3 | United States;Canada | |
| 63 | NCT00638456 | February 2008 | 26 August 2019 | Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis | Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial | Eosinophilic Esophagitis | Drug: Budesonide plus Prevacid;Drug: placebo plus Prevacid | Ranjan Dohil | Meritage Pharma, Inc. | Not recruiting | 1 Year | N/A | All | 32 | Phase 2 | United States |
| 64 | NCT01404832 | October 2007 | 19 October 2017 | The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors | The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors | Gastroesophageal Reflux Disease;Eosinophilic Esophagitis | Drug: Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | Dallas VA Medical Center | TAP Pharmaceutical Products Inc. | Not recruiting | 18 Years | N/A | All | 102 | Phase 4 | United States |
| 65 | NCT00511316 | August 2007 | 17 November 2015 | Trial of Montelukast in Eosinophilic Esophagitis | A Randomized Placebo-Controlled Trial of Montelukast in Maintenance Therapy of Asymptomatic Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Montelukast/ Singulair;Drug: Placebo | Mayo Clinic | Merck Sharp & Dohme Corp.;Merck Sharp & Dohme Corp. | Not recruiting | 18 Years | 100 Years | Both | 41 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT00523354 | August 2007 | 19 February 2015 | Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis | Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis | Esophagitis | Drug: Infliximab | Swiss EE Study Group | Not recruiting | 18 Years | 70 Years | Both | Phase 2 | Switzerland | ||
| 67 | NCT00426283 | January 2007 | 19 October 2017 | A Study of Flovent in Patients With Eosinophilic Esophagitis | A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Flovent;Other: Placebo | Marc Rothenberg | Not recruiting | 3 Years | 30 Years | All | 42 | Phase 2 | United States | |
| 68 | NCT00358449 | September 11, 2006 | 16 December 2017 | Intravenous Mepolizumab In Children With Eosinophilic Esophagitis | A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) | Oesophagitis, Eosinophilic | Drug: mepolizumab | GlaxoSmithKline | Not recruiting | 2 Years | 17 Years | All | 84 | Phase 2 | United States;Australia;Canada;United Kingdom | |
| 69 | EUCTR2005-006074-10-GB | 15/06/2006 | 19 March 2012 | A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitis | A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitis | Eosinophilic oesophagitis | Product Name: Mepolizumab Product Code: SB-240563 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Mepolizumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- | GlaxoSmithKline Research & Development Ltd. | Authorised | Female: yes Male: yes | 72 | United Kingdom | ||||
| 70 | NCT00271349 | December 2005 | 1 June 2015 | Budesonide for Eosinophilic Esophagitis | Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study | Eosinophilic Esophagitis | Drug: Budesonide | Swiss EE Study Group | Not recruiting | 14 Years | 70 Years | Both | 28 | Phase 2 | Switzerland | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT00123630 | November 2005 | 19 October 2017 | A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab | A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab | Esophagitis | Drug: omalizumab;Drug: Placebo | University of Utah | Novartis Pharmaceuticals | Not recruiting | 12 Years | 60 Years | All | 30 | Phase 2 | United States |
| 72 | NCT00275561 | November 2005 | 19 October 2017 | Topical Steroid Treatment for Eosinophilic Esophagitis | A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Fluticasone;Drug: Placebo | Mayo Clinic | Not recruiting | 18 Years | 60 Years | All | 42 | Phase 2 | United States | |
| 73 | NCT00148603 | September 2005 | 19 February 2015 | Montelukast in the Treatment of Duodenal Eosinophilia | Montelukast in the Treatment of Duodenal Eosinophilia in Children With Dyspepsia: Effect on Eosinophil Density and Activation in Relation to Pharmacokinetics | Eosinophilic Gastroenteritis;Dyspepsia | Drug: montelukast | Children's Mercy Hospital Kansas City | Merck Sharp & Dohme Corp. | Not recruiting | 8 Years | 17 Years | Both | 24 | N/A | United States |
| 74 | NCT00123656 | August 2004 | 19 February 2015 | Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis | Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis | Esophagitis | Drug: esomeprazole;Drug: fluticasone | University of Utah | American Society for Gastrointestinal Endoscopy | Not recruiting | 18 Years | 80 Years | Both | 30 | Phase 2 | United States |
| 75 | NCT00084097 | June 2, 2004 | 16 December 2017 | Omalizumab to Treat Eosinophilic Gastroenteritis | Pilot Study of Omalizumab in Eosinophilic Gastroenteritis | Gastroenteritis | Drug: Omalizumab | National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | 12 Years | 76 Years | All | 30 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT00266578 | October 2002 | 19 February 2015 | A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders | Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial | Eosinophilic Esophagitis | Drug: Fluticasone Propionate | Marc Rothenberg | Not recruiting | 3 Years | 30 Years | Both | 30 | Phase 3 | United States | |
| 77 | NCT00266565 | December 2001 | 16 December 2017 | Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome | A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes | Hypereosinophilic Syndromes;Eosinophilic Gastroenteritis;Churg-Strauss Syndrome;Eosinophilic Esophagitis | Drug: Mepolizumab | Children's Hospital Medical Center, Cincinnati | Not recruiting | 18 Years | 65 Years | All | 24 | Phase 1/Phase 2 | United States | |
| 78 | NCT00017862 | June 2001 | 19 February 2015 | Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome | A Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional Therapy | Hypereosinophilic Syndrome | Drug: SCH55700 | National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | N/A | N/A | Both | 10 | Phase 2 | United States |